
The article from the Egypt Healthcare Authority (EHA) discusses the successful implementation and benefits of using CTO-PCI (Chronic Total Occlusion Percutaneous Coronary Intervention) technology to treat chronic coronary artery occlusion in Egypt. Here are some key points to consider:
- Success of Procedures: The EHA reported the successful treatment of three elderly patients (all over 60 years old) using CTO-PCI technology with micro-catheters and specialised wires at the International Medical Complex in Luxor. The procedures achieved a 100% success rate.
- Cost and Universal Health Coverage: The cost of CTO-PCI procedures outside the universal health coverage system exceeds 500,000 Egyptian pounds. However, under the universal health insurance system, patients contribute no more than 400 EGP.
- Medical Team and Expertise: The procedures were conducted by a highly skilled team of medical consultants, including top professors, cardiologists, and specialised nursing and technical staff. Key team members included Dr. Tarek Rashid, Head of the Scientific Committee for Cardiology, and Dr. Zein El-Abidin Abdel-Latif, Head of the Cardiology and Catheterization Department.
- Commitment to Innovation: The EHA emphasised its commitment to innovation and continuous development, adopting the latest global medical advances and introducing cutting-edge technologies across all medical specialties, particularly in cardiology.
- Patient Benefits: The patients treated were suffering from angina and severe pain due to coronary artery occlusion. The use of CTO-PCI technology significantly improved their quality of life.
- Healthcare Model: The EHA aims to provide a modern healthcare model in Egypt by ensuring access to the latest global medical advancements and maintaining a team of expert consultants.
This initiative reflects the Authority‘s dedication to providing innovative medical technologies and achieving high-quality care for patients under the universal health insurance system.
Recent Posts
Advancements in Intranasal Drug Delivery: Hovione and IDC Launch Commercial Platform
Hovione and IDC have announced that their Intranasal Drug Delivery platform has advanced to commercial readiness, with the lead single-use nasal dry powder device now available for partnerships. This integrated solution combines API development, particle engineering, formulation, capsule filling,...
Portugal Cannabis Market Decline: Analyzing the Impact of Licensing Reductions
The Portugal cannabis market decline has accelerated sharply since January 2026. Official Infarmed IP lists show that more than 30 percent of entities authorised for medicinal cannabis activities in Portugal have been suspended or permanently removed, producing a measurable contraction across cul...
Boosting Africa Vaccine Manufacturing: A New Era of Local Production and Supply Security
Africa Vaccine Manufacturing stands to benefit from ongoing talks between Africa CDC and Aspen Pharmacare aimed at securing long-term vaccine supply agreements that strengthen local production capacity across the continent. The discussions focus on selecting priority antigens, scaling annual outp...